Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).


Clinical Trial Description

One of the greatest impediments to patient treatment satisfaction with current inhaled treprostinil therapy is inconvenience. Currently, PAH patients using inhaled treprostinil may require more than 36 breaths per day using a nebulizer requiring daily set up and cleaning. The use of a discrete, hand-held dry powder inhaler to deliver treprostinil to the lungs could represent a major improvement in convenience and patient satisfaction, thereby improving the quality of life for PAH patients. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using Liquidia's PRINT® Technology (Particle Replication in Nonwetting Templates), as an alternative to current inhaled treprostinil therapy for the treatment of patients with PAH (WHO Group 1). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03992755
Study type Interventional
Source Liquidia Technologies, Inc.
Contact
Status Active, not recruiting
Phase Phase 3
Start date July 18, 2019
Completion date March 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Recruiting NCT05339087 - Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH Phase 2
Completed NCT03528902 - Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension Phase 2
Completed NCT02859194 - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients N/A
Withdrawn NCT00722254 - Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder N/A
Withdrawn NCT01645826 - Efficacy Study of Cardizem in Pulmonary Arterial Hypertension N/A
Completed NCT03399604 - Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil Phase 3